A groundbreaking study has unveiled a promising new therapy for lymphoma using the radioactive isotope terbium-161 ...

3月8日，《Nature》期刊刊登了一篇名为“Evidence of near-ambient superconductivity in a N-doped lutetium hydride”的论文，是美科学家团队重提“室温超导”话题，轰动了整个物理界..... 电子工程专辑讯 3月8日，《Nature》期刊刊登了一篇名为“Evidence of near-ambient ...

The cancer can be effectively combated with the radioactive element terbium. However, the therapy has not yet been tested on ...

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

Outcomes associated with the use of Lutetium-177. Died 1614 14.2 Disabled 42 0.4 Hospitalized 658 5.8 Life Threatening 52.5 Non-Serious 7760 68.4 Other Outcomes 1220 10.8 Total 11346 100.0 This is an ...

Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC). This is an ...

Lutetium-177-PSMA-617 (177Lu-PSMA-617), a type of targeted radiation therapy, is effective for men with advanced prostate cancer, even if they were previously treated with another radiation ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is commonly used to treat certain people with prostate cancer that is PSMA-positive and has spread to other parts of the body (metastatic).

What is Lutathera used for? Lutathera (lutetium lu 177 dotatate) is commonly used to treat certain types of tumors in your digestive system. Specifically, Lutathera treats gastroenteropancreatic ...

And so, what it's effectively done is extend my life for five years." Lutetium-177 is a "tolerable and effective" treatment option for metastatic castrate-resistant prostate cancer, an aggressive ...

with first metastatic castrate resistant prostate cancer patients expected to enroll this quarter The Phase 1 data shows that Lutetium (177 Lu) rhPSMA-10.1 Injection has high ratios for absorbed ...